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IntroductIon
Hepatitis B is the most common serious liver infection in the world, with about 350 million 
people who are infected with the hepatitis B virus (HBV) and about 1 million deaths annually. 
Hepatitis B is characterized by an acute and a chronic phase, if the subject fails to produce 
adequate immune response. About 5-10% of adults infected with HBV go on to develop chronic 
infection and become chronic carriers (CHB); moreover, the liver damage, if not stopped, 
continues until cirrhosis or hepatocellular carcinoma. In the natural history of HBV infection, 
the most important event is HBeAg seroconversion, characterized by loss of HBeAg (a specific 
antigen of the virus) and development of Anti-HBe antibodies (HBeAg-positive patients). If the 
seroconversion has occurred early (when liver damage is not yet significant) and is maintained, 
long-term prognosis is excellent. The disease can follow a more aggressive course if active 
viral replication persists despite anti-HBe positivity. This state, characterized by continuing 
viral replication, has been termed as HBeAg-negative CHB, and is the most prevalent form 
in Italy. At the moment, there are 4 approved antiviral drug classes, with different antiviral 
efficacy, for the treatment of chronic hepatitis B: interferons, nucleoside analogues, nucleotide 
analogues, and cyclopents. The primary target of the treatment is a prolonged suppression of 
viral replication, in order to avoid long term complications and increase survival.
IndIcatIons and dosIng
Entecavir (ETV) is a new active substance, a guanosine analogue with selective activity 
against HBV, indicated for the treatment of chronic hepatitis B in adults with compensated liver 
disease, evidence of active viral replication and signs of liver damage. The drug is available in 
two pharmaceutical forms: film-coated tablets, which contain 0.5 or 1 mg of ETV anhydrous, 
and oral solution (0.05 mg/ml of active substance). Entecavir is taken once daily, with a dose 
of 0.5 mg for patients never treated with a nucleoside analogue and with a dose of 1 mg 
in patients refractory to lamivudine (LVD). This drug is currently included by AIFA (Agenzia 
Italiana del Farmaco) in a drug efficacy and safety monitoring program.
PharmacokInetIcs
Pharmacokinetics of ETV is characterized by a moderate inter-individual variability. Co-
administration of food reduces Cmax by about 50% and AUC by 20%, while Tmax is increased; 
PK/PD modeling showed that in treatment of naïve subjects ETV could be taken with or without 
food, but in LVD-refractory patients this drug must be taken at least 2 hours before or after 
meals. Cmax and AUC increased in patients with renal impairment and in elderly subjects; for 
this population base dose adjustment is required.
PharmacodynamIcs
Entecavir is a cyclopentyl guanine analogue and inhibits selectively HBV polymerase (reverse 
transcriptase) by competing with the natural substrate deoxyguanosine triphosphate. 
effIcacy and safety 
Three phase III trials have been conducted to test ETV efficacy and safety: two of them (AI463-
022 and AI463-027) in nucleoside-naïve subjects, and one (AI463-026) in lamivudine-refractory 
subjects. The primary objective of these studies was to evaluate the efficacy of ETV versus 
lamivudine treatment in chronic hepatitis B patients with compensated liver disease. The 
primary efficacy measure for nucleoside-naïve subjects trials is the proportion of subjects 
who achieved histological improvement, defined as ≥2 points decrease in the Knodell 
necroinflammatory score with no worsening of fibrosis compared to baseline. In the AI463-026 
study (LVD-refractory subjects) there are two co-primary endpoints, the histologic improvement 
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and the composite endpoint, definite as the proportion of subjects with undetectable HBV DNA 
(<0.7 mEq/ml) and normalization of serum ALT (<1.25 x ULN). Subjects are differentiated 
in HBeAg-positive (HBeAg+) and HBeAg-negative (HBeAg-): HBeAg is a portion of the core 
antigen of the virus generally released during the infectiveness phase, and its persistence in 
the serum is associated with active chronic hepatitis. Duration of all main studies was 52 weeks 
for subjects with complete response (HBV DNA <0.7 mEq/ml and HBeAg-) or no response 
(HBV DNA >0.7 mEq/ml), extended to 92 weeks for partial responders (HBV DNA <0.7 mEq/ml 
and HBeAg+).
The statistical histological, biological and virological superiority of ETV compared to LVD was 
demonstrated at 48 and 24 weeks, and also in patients resistant to LVD. The safety profile of 
the drug is comparable to the one of LVD, although the question about ETV cancerogenity is 
still open; animals studies suggest a potential cancerogenic effect for the drug, and clinical 
follow-up data reported an incidence of 3.5/1,000 cases of hepatocarcinomas in ETV-treated 
patients.
study design comparator efficacy safety
naive subjects
AI463-022 1,056 HBeAg+ patients. 
Multicenter (137), 
randomized 1:1,  
double-blind study
ETV 0.5 mg QD (354 pt)
LVD 100 mg QD (355 pt)
Histological improvement
(NC=F): ETV 72% vs LVD 62%.
ETV is superior to LVD, p=0.0085
(NC=M): ETV 77% vs LVD 72%. 
ETV is non-inferior to LVD, p=0.191
Most common AEs:
headache (9%), fatigue 
(6%), dizziness (4%), and 
nausea (3%)
AI463-027 1,468 HBeAg-/antiHBe+ 
patients. Multicenter 
(146), randomized 1:1, 
double-blind study
ETV 0.5 mg QD (325 pt)
LVD 100 mg QD (313 pt)
Histological improvement
(NC=F): ETV 70% vs LVD 61%.
ETV is superior to LVD, p=0.0143
(NC=M): ETV 78% vs LVD 70%.
ETV is superior to LVD, p=0.0212
LVd-refractory subjects
AI463-026 420 HBeAg+ patients. 
Multicenter (84), 
randomized 1:1, double-
blind study
ETV 1 mg QD (141 pt)
LVD 100 mg QD (145 pt)
Histological improvement
(NC=F): ETV 55% vs LVD 28%.
ETV is superior to LVD, p=<0.001
(NC=M): ETV 62% vs LVD 33%.
ETV is superior to LVD, p=<0.001
Composite endpoint* 
(NC=F): ETV 55% vs LVD 4%.
ETV is superior to LVD, p=<0.001
(NC=M): ETV 57% vs LVD 4%.
ETV is superior to LVD, p=<0.001
table II
Summary of main studies investigating efficacy and safety of entecavir in hepatitis B chronic patients. Subjects with missing data at week 
48 can be included (NC=F) or excluded (NC=M) from the analysis
 *intended as HBV DNA <0.7 mEq/ml and serum ALT <1.25 x ULN
 AEs = adverse events; ETV = entecavir; LVD = lamivudine; QD = once daily
absorption
Bioavailability cmax tmax Binding to plasma proteins
70% 4.2 ng/ml - 8.2 ng/ml  
(for 0.5 mg and 1 mg dose 
respectively)
0.5 – 1.5 h 13%
metabolism and distribution
Volume of 
distribution
metabolism metabolites
Biological activity  
of metabolites
Vz/F : 2,550 to 
7,708 l
Low metabolism 
(metabolites excreted are 
<10% of administered dose)
Minor amounts of phase 2 
metabolites (glucuronide, 
sulfate conjugates) 
Not present
elimination
clearance Plasma terminal half-life elimination Interactions 
400 ml/min 130 h 76% urine, 6% faeces Drugs that reduce renal 
function or compete for active 
tubular secretion
table I
Absorption, distribution, metabolism and elimination of entecavir after oral administration
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economIc eVaLuatIons
Costs of currently approved products for chronic hepatitis B treatment can vary widely: factors 
affecting costs include the direct cost of the drug, length of treatment, and complication 
associated with continued therapy, like development of resistance or intolerable adverse 
events. 
Currently there are six approved drugs for the hepatitis B therapy: interferon alpha-2b, 
pegylated interferon alpha-2a, and four oral monotherapeutic agents (adefovir dipivoxil, 
entecavir, lamivudine and telbivudine). Injectable interferons and oral drugs represent two 
different pharmacological approaches, the first based on host immunity stimulation, and the 
other on a direct antiviral action. Furthermore, polymerase inhibitors need to be indefinitely 
administered since they are unable to induce a sustained response, even after years of 
continuous administration. Nevertheless, costs of treatment with oral drugs represent a drastic 
reduction compared to subcutaneous therapy, and these treatments are also associated with a 
good response rate and an excellent safety profile, making the overall treatment cost effective. 
The main limitation of these drugs is the emerging of resistance during the treatment: in 
particular patients treated with lamivudine, which is effective and not expensive, reported high 
resistance rates, ranging from 14%-32% after 1 year of therapy to 58% with 2-3 years. 
study comparators methods results conclusions
Yuan  
et al, 
2008 (b)
ETV, LVD Subjects: 519 
Efficacy end point (48 weeks): pts achieving 
HBV DNA < 300 copies/ml
Daily prices assumed: ETV 40 RMB (€ 3.64), 
LVD 16.71 RMB (€ 1.52)
Direct medical cost, utility scores: estimated 
from published China specific data
3% annual discount applied
Time horizon: 1 year 
Setting: China
Efficacy: ETV was superior 
to LVD (78.7% vs 46.7%, 
p<0.05) 
ICER: 17,590 RMB/QALY 
gained (about € 1,600) for 
ETV
ETV is cost effective 
in treating hepatitis B 
pts in China, based 
on the World Health 
Organization’s 
recommended maximum 
willingness to pay 
threshold
Veenstra 
et al, 
2008
ETV, ADF, LVD; Subjects: HBeAg- pts. Addition of ADF or ETV 
for LVD-refractary pts
Disease progression probabilities, costs and 
quality of life data derived from literature
Evaluated 5-year, 10-year, lifetime and 5 on-1 
off treatment durations
Time horizon: lifetime 
Setting: USA
All three drugs are cost-
effective 
5 on-1 off strategy was the 
most cost-effective 
ICER: 148,200 $/QALY for 
lifetime vs 5 on-1 off for ETV
In HBeAg-  CHB 
infection, a 5 on-1 off 
treatment strategy with 
ETV is cost-effective 
compared to alternative 
strategies
Yuan  
et al, 
2008 (a)
ETV, LVD Subjects: HBeAg+ pts
Efficacy end point (48 weeks): pts achieving 
HBV DNA < 300 copies/ml
Annual prices assumed: ETV $ 7,365,  
LVD $ 2,604
Efficacy and safety data from clinical trials, 
other model parameters from literature
3% annual discount applied
Time horizon: 10 years
Setting: USA
Efficacy: ETV superior to LVD 
(69.1% vs 39.8%, p<0.001)
ICER: 3,230 $/QALY gained 
for ETV
ETV given for up to 10 
years would be highly 
cost-effective in  
HBeAg+ pts
Veenstra 
et al, 
2007
ETV, LVD Subjects: 709 HBeAg+ pts. Addition of ADF 
for LVD-refractary pts
Clinical and economic inputs from publicly 
available data 
Analysis performed by a Markov model
Time horizon: lifetime
Setting: USA
Estimated 10-year 
cumulative incidence of 
cirrhosis: ETV 20.5%,  
LVD 22.8%
ICER: 7,600 $/QALY 
ETV is cost-effective 
compared with LVD 
with ADF salvage or 
combination therapy
Kanwal  
et al, 
2005
ETV, ADF, LVD Subjects: HBV pts with cirrhosis
The study evaluated the cost-effectiveness of 
six strategies: 
(1) No HBV treatment (“do nothing”)
(2) LVD monotherapy
(3) ADF monotherapy
(4) LVD with crossover to ADF on resistance 
(“ADF salvage”)
(5) ETV monotherapy
(6) LVD with crossover to ETV on resistance 
(“ETV salvage”)
(1) least effective yet least 
expensive
(3) vs (1) incremental cost of 
$ 19,731
(5) vs (3) more effective yet 
more expensive, incremental 
cost 25,626 $/QALY
(2), (4) and (6) not cost-
effective
(4) vs (6) more effective and 
less expensive
Both ETV and ADF are 
cost-effective in pts with 
HBV cirrhosis; choosing 
between ADF and ETV 
is highly dependent on 
available budgets. In 
pts who developed LVD 
resistance, “ADF salvage” 
appears more effective 
and less expensive than 
“ETV salvage”
table III
Economic evaluations of the cost-effectivness of entecavir in the therapy of chronic hepatitis B
 ADF = adefovir; ETV = entecavir; LVD = lamivudine; pts = patients; RMB = renminbi, currency of the People’s Republic of China
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In Table III we reviewed the main economic evaluations we found in PubMED for ETV. Generally 
this drug appears to be cost-effective in chronic hepatitis B therapy, particularly if compared 
to LVD. LVD, the first oral nucleoside analog approved for the treatment of CHB, presents a 
lower acquisition cost ($ 4,671 less per patient per year respect to ETV), but patients treated 
with this drug reported high resistence rates (14-32% vs 0% of ETV); both adefovir and ETV 
present lower viral resistance rates, but are more expensive. The cost-effectiveness of ETV 
compared with adefovir for nucleos(t)ide treatment-naïve patients is in need of investigation.
In Table IV we calculated the monthly pharmaceutical cost in Italy of available hepatitis B 
treatment: this is not to be intended as a cost-minimization analysis, but as a simple overlook 
of currently available treatments. Considered dosages are those derived from reference trials 
or from the SPCs of the products. For interferon alpha-2b, we considered a dosing of 9-10 
MUI/3 times a week for HBeAg+ patients and of 5-6 MUI/3 times a week for HBeAg-, as seen in 
a national treatment protocol. Prices of the drugs are derived from Informatore Farmaceutico 
2008: we always considered ex-factory price. 
Globally, the monthly cost of telbivudine is nearly the same of entecavir (€ 379), and similar to 
the one of adefovir; the cost of peginterferon is almost twice, and the less costly drug results 
lamivudine, with a monthly cost of about € 54.
Name of the Medicinal Product Baraclude 
Marketing Authorisation Holder Bristol-Myers Squibb Pharma EEIG
Active Substance Entecavir 
Pharmaco-therapeutic Group 
Nucleoside and nucleotide reverse transcriptase 
inhibitors 
ATC Code J05FA10 
Date of issue of Marketing Authorisation valid 
throughout the European Union 
26 June 2006
rs frequency Package Price 
ex-factory 
price
monthly 
price**
self-injectable drugs
Interferon alpha-2b (HBeAg+ pts) PHT 10 MUI 3 times a week 1 vial 88.46 53.60 611.03
Interferon alpha-2b (HBeAg+ pts) PHT 18 MUI 3 times a week 1 vial 147.46 89.35 565.87
Interferon alpha-2b (HBeAg+ pts) PHT 25 MUI 3 times a week 1 vial 203.69 123.42 562.78
Interferon alpha-2b (HBeAg- pts) PHT 10 MUI 4 times a week 1 vial 88.46 88.46 353.75
Interferon alpha-2b (HBeAg- pts) PHT 18 MUI 5 times a week 1 vial 147.46 147.46 327.61
Interferon alpha-2b (HBeAg- pts) PHT 25 MUI 6 times a week 1 vial 203.69 203.69 325.82
Peginterferon alpha-2a* PHT 180 mcg 3 times a week 1 vial 321.41 194.75 778.98
oral drugs
Adefovir dipivoxil* H 10 mg Daily 30 tablets 705.55 427.50 399.00
Entecavir* H 0.5 mg Daily 30 tablets 670.28 406.13 379.05
Entecavir* H 1 mg Daily 30 tablets 670.28 406.13 379.05
Lamivudine PHT 100 mg Daily 28 tablets 89.57 54.27 54.27
Lamivudine PHT 5 mg Daily Oral solution (240 ml) 38.43 23.29 54.33
Telbivudine* H 600 mg Daily 28 tablets 625.58 379.04 379.04
table IV
Monthly pharmaceutical costs of different available therapies for chronic hepatitis B treatments
 *Price neglects further negotiated discounts on supplies for NHS
 ** Four weeks
 H = hospital prontuary; PHT = hospital-territorial prontuary; pts = patients; RS = reimbursement status
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